IL-33 Alleviated Brain Damage via Anti-apoptosis, Endoplasmic Reticulum Stress, and Inflammation After Epilepsy

Yuan Gao,Chengliang Luo,Yi Yao,Junjie Huang,Huifang Fu,Chongjian Xia,Guanghua Ye,Linsheng Yu,Junge Han,Yanyan Fan,Luyang Tao
DOI: https://doi.org/10.3389/fnins.2020.00898
IF: 4.3
2020-08-31
Frontiers in Neuroscience
Abstract:Interleukin (IL)-33 belongs to a novel chromatin-associated cytokine newly recognized by the IL-1 family, and its specific receptor is the orphan IL-1 receptor (ST2). Cumulative evidence suggests that IL-33 plays a crucial effect on the pathological changes and pathogenesis of central nervous system (CNS) diseases and injuries, such as recurrent neonatal seizures (RNS). However, the specific roles of IL-33 and its related molecular mechanisms in RNS remain confused. In the present study, we investigated the protein expression changes and co-localized cell types of IL-33 or ST2, as well as the effect of IL-33 on RNS-induced neurobehavioral defects, weight loss, and apoptosis. Moreover, an inhibitor of IL-33, anti-IL-33 was performed to further exploited underlying mechanisms. We found that administration of IL-33 up-regulated the expression levels of IL-33 and ST2, and increased the number of its co-localization with Olig-2-positive oligodendrocytes and NeuN-positive neurons at 72 h post-RNS. Noteworthily, RNS-induced neurobehavioral deficits, bodyweight loss, and spatial learning and memory impairment, as well as cell apoptosis, were reversed by IL-33 pretreatment. Additionally, the increase in IL-1β and TNF-α levels, up-regulation of ER stress, as well as a decrease in anti-apoptotic protein Bcl-2 and an increase in pro-apoptotic protein CC-3 induced by RNS are prevented by administration of IL-33. Moreover, IL-33 in combination with Anti-IL-33 significantly inverted the effects of IL-33 or Anti-IL-33 alone on apoptosis, ER stress, and inflammation. Collectively, these data suggest that IL-33 attenuates RNS-induced neurobehavioral disorders, bodyweight loss, and spatial learning and memory deficits, at least in part through mechanisms involved in inhibition of apoptosis, ER stress, and neuro-inflammation.
neurosciences
What problem does this paper attempt to address?
This paper aims to explore the alleviating effect of interleukin - 33 (IL - 33) on brain injury after recurrent neonatal seizures (RNS) and its potential mechanisms. Specifically, the researchers experimentally observed the effects of IL - 33 on neurobehavioral deficits, weight loss, spatial learning and memory impairments, and apoptosis caused by RNS, and explored the role of IL - 33 in inhibiting endoplasmic reticulum stress (ERS), inflammatory responses, etc. ### Research Background - **Epilepsy** is a common neurological disease, characterized by recurrent convulsions, often accompanied by transient brain dysfunction, emotional and cognitive dysfunction. - **RNS** (recurrent neonatal seizures) is a special form of epilepsy, which poses a serious threat to children's health. - **IL - 33** is a new member of the IL - 1 family, and its specific receptor is the orphan IL - 1 receptor (ST2). Previous studies have shown that IL - 33 plays an important role in the pathological changes of central nervous system (CNS) diseases, but its specific role and molecular mechanism in RNS are still unclear. ### Research Objectives - **Main objective**: To evaluate the protective effect of IL - 33 on brain injury after RNS. - **Specific objectives**: - To observe the effects of IL - 33 on neurobehavioral deficits, weight loss, spatial learning and memory impairments caused by RNS. - To explore the role of IL - 33 in inhibiting apoptosis, endoplasmic reticulum stress (ERS) and inflammatory responses. - To further verify the mechanism of action of IL - 33 using an IL - 33 inhibitor (Anti - IL - 33). ### Experimental Design - **Animal model**: Use Sprague - Dawley (SD) rats to establish the RNS model. - **Experimental groups**: - Sham + PBS group - RNS + PBS group - RNS + IL - 33 group - RNS + Anti - IL - 33 group - RNS + Anti - IL - 33+IL - 33 group ### Main Results - **Changes in IL - 33 expression**: RNS significantly decreased the expression levels of IL - 33 and ST2, while IL - 33 pretreatment significantly increased the expression of these proteins. - **Neurobehavioral tests**: IL - 33 pretreatment reversed the neurobehavioral deficits caused by RNS, including performance in the forelimb suspension test, negative geotaxis test, cliff avoidance test, and open - field test. - **Weight recovery**: IL - 33 pretreatment significantly improved the weight loss caused by RNS. - **Spatial learning and memory**: In the Morris water maze test, IL - 33 pretreatment significantly shortened the escape latency and increased the frequency of crossing the platform area. - **Inflammatory response and NF - κB activity**: IL - 33 pretreatment significantly decreased the levels of TNF - α and IL - 1β caused by RNS and inhibited the activity of NF - κB. ### Conclusion IL - 33 significantly alleviates the neurobehavioral deficits, weight loss, and spatial learning and memory impairments caused by RNS by inhibiting apoptosis, endoplasmic reticulum stress, and neuroinflammation. These findings provide a theoretical basis for the development of new RNS treatment strategies.